Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0IJ7O
|
||||
| Former ID |
DNC000928
|
||||
| Drug Name |
Metastat
|
||||
| Drug Type |
Small molecular drug
|
||||
| Formula |
C19H17NO7
|
||||
| CAS Number |
CAS 15866-90-7
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | 72 kDa type IV collagenase | Target Info | Inhibitor | [535550] | |
| PANTHER Pathway | Alzheimer disease-presenilin pathway | ||||
| Pathway Interaction Database | LPA receptor mediated events | ||||
| Plasma membrane estrogen receptor signaling | |||||
| Osteopontin-mediated events | |||||
| Validated transcriptional targets of AP1 family members Fra1 and Fra2 | |||||
| Angiopoietin receptor Tie2-mediated signaling | |||||
| Direct p53 effectors | |||||
| amb2 Integrin signaling | |||||
| ATF-2 transcription factor network | |||||
| FOXM1 transcription factor network | |||||
| Regulation of nuclear beta catenin signaling and target gene transcription | |||||
| Syndecan-2-mediated signaling events | |||||
| References | |||||
| Ref 521425 | ClinicalTrials.gov (NCT00001683) A Phase I Study of Oral COL-3 (NSC-683551), a Matrix Metalloproteinase Inhibitor, in Patients With Refractory Metastatic Cancer. U.S. National Institutes of Health. | ||||
| Ref 527241 | A phase I and pharmacokinetic study of Col-3 (Metastat), an oral tetracycline derivative with potent matrix metalloproteinase and antitumor properties. Clin Cancer Res. 2004 Oct 1;10(19):6512-21. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.